Paul Wotton

Paul brings an expert perspective on platform growth opportunities from a 35-year career leading multiple global biotechnology and pharmaceutical companies. He is a serial entrepreneur and inventor with experience spanning scientific research, product development, and transformational business transactions. Paul has served as Chief Executive Officer of Obsidian Therapeutics, Sigilon Therapeutics (NASDAQ:SGTX), Ocata Therapeutics (acquired by Astellas), Antares Pharma (acquired by Halozyme), and Topigen Pharmaceuticals. He currently serves on the Boards of Combined Therapeutics, Kytopen, Vericel Corporation (NASDAQ: VCEL), and Cynata Therapeutics (ASX: CYP), and is a founder and Director of Avenge Bio. He received his B.Pharm from University College London and his Ph.D. in pharmaceutical sciences from the University of Nottingham.